arGEN-X advances a third therapeutic antibody program into preclinical development: http://t.co/hBB8aUOQ
posted 17 hours ago
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
Pronota NV today announced the close of a Series C financing, raising EUR 3.7 million from existing investors; LSP, Gimv, Biotech Fund Flanders, KBC Private Equity, Johnson & Johnson Development Corporation, VIB, MP Healthcare and MedSciences Capital, and a company founder. read more
Biocartis, a company developing and commercializing compact molecular diagnostic (MDx) systems designed to drive personalized medicine and improve the diagnosis and management of disease, today announced the appointment of Clark Harrison as its new Chief Operating Officer. Clark is the first senior appointment following the announcement of new CEO Greg Parekh. read more
Na 3,5 succesjaren geeft Ann Van Gysel begin 2012 de fakkel door aan Ann De Beuckelaer als nieuwe Algemeen Directeur van FlandersBio, de netwerkorganisatie die sinds 2004 de drijvende kracht is voor de stevige groei van de Vlaamse kennisgebaseerde biotechindustrie. read more
Biocartis, a company developing and commercializing compact molecular diagnostic (MDx) systems designed to drive personalized medicine and improve the diagnosis of disease, today announced the appointment of Dr. Nayan Gregory Parekh as its new Chief Executive Officer. read more
ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces today that Thomas Clay has been appointed as a non-executive director with immediate effect. read more
Complix NV, a biopharmaceutical company focused on the discovery and development of Alphabodies™, a novel class of protein therapeutics, announced today that it has appointed Dr Thore Hettmann as Head of Therapeutic Development. With this appointment Complix is further strengthening its management team as the Company is transitioning to its next level of development. read more
The Board of Directors of Applied Maths has appointed Koen Janssens as CEO of Applied Maths. Koen Janssens holds a Master degree in Applied Economics and a Master of Science in Bioinformatics (Katholieke Universiteit Leuven). During the last seven years, he has been increasingly involved in the operational management of the company. In his new role as CEO, he will be supported by an Executive Committee, consisting of Paul Vauterin, Director of Software Development and Bruno Pot, Director of Business Development. Luc Vauterin, co-founder of Applied Maths, stepped down as CEO in June of this year but remains closely involved with Applied Maths as Scientific Advisor. read more
